Welcome to our dedicated page for Biomind Labs news (Ticker: BMNDF), a resource for investors and traders seeking the latest updates and insights on Biomind Labs stock.
Biomind Labs Inc. (BMNDF) is a biotechnology innovator developing advanced therapies for neurological and psychiatric disorders through novel drug delivery systems. This page provides investors and industry observers with timely updates on clinical trials, regulatory milestones, and research developments critical to understanding the company's progress.
Access comprehensive collection of official press releases and curated news covering BMNDF's preclinical studies, strategic partnerships, and advancements in treating conditions linked to neuroinflammation. Resources are organized to highlight material events including Phase II trial initiations, intellectual property updates, and nanotechnology innovations enhancing treatment efficacy.
Key updates include progress on tryptamine-based formulations, metabolic disorder research intersecting with neurological pathways, and collaborations advancing psychedelic-derived therapies. All content is maintained to reflect BMNDF's commitment to rigorous scientific validation and regulatory compliance.
Bookmark this page for streamlined access to verified updates about Biomind Labs' pioneering work in biopharmaceutical development. Check regularly for new insights into their pipeline candidates and emerging treatment paradigms.
Biomind Labs responds positively to U.S. government's progressive stance on psychedelic therapies, marked by the nomination of a new Health Secretary supportive of innovative mental health solutions. The company's drug candidate BMND08 showed 100% efficacy in Phase II trials, achieving remission from depression, anxiety, and stress by week 5. The company plans to pursue Breakthrough Therapy Designation with the FDA. Biomind's portfolio includes several drug candidates: Triptax™ (FDA IND clearance), BMND01 (DMT), BMND07 (5-MeO-DMT), BMND02 (nasal), and BMND08 (sublingual formulation).
Biomind Labs Inc. (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI) has announced plans to advance a new Phase II clinical trial for its proprietary compound BMND06, targeting obesity treatment through neurological pathways. Key findings from pre-clinical studies include:
1. BMND06 is physiologically safe with low toxicity and no mutagenic effects.
2. It significantly reduces LPS-induced IL-6 levels in colon cancer cell lines, outperforming dexamethasone by fivefold.
3. The compound shows potential in treating obesity as a neurological condition, addressing the global obesity epidemic affecting 2.3 billion people worldwide.
CEO Alejandro Antalich emphasized BMND06's potential to redefine obesity treatment by targeting neuroinflammation and neural pathways regulating metabolism and energy balance.
Biomind Labs has initiated a Phase II clinical trial for its BMND08 candidate, a sublingual formulation of 5-MeO-DMT, targeting anxiety and depression in Alzheimer’s disease. Led by Dr. Martín Bruno and involving 40 participants aged 50-75, the trial aims to assess the association of these symptoms with Amnestic Mild Cognitive Impairment, which could predict progression to Alzheimer’s. The trial highlights the increasing global burden of dementia, anticipated to reach 139 million by 2050, emphasizing the urgent need for effective treatments. Biomind Labs focuses on innovative therapies for neurological disorders, aiming to provide affordable treatment options.
Biomind Labs Inc. (OTC: BMNDF) has achieved a significant milestone by optimizing a new extraction method that enhances the purity and yield of N,N-dimethyltryptamine (DMT) for their New Chemical Entity (NCE), Triptax™. This method has received FDA Investigational New Drug clearance, supporting future clinical trials for treating neurological disorders such as depression. The scalable and environmentally friendly production aligns with the company’s goals of affordable pharmaceuticals. CEO Alejandro Antalich emphasized the cost benefits and compliance with Good Manufacturing Practices, marking progress in their pharmaceutical development.
Biomind Labs has developed a novel sublingual formulation for its 5-MeO-DMT-based drug candidate BMND08, aimed at treating depression and anxiety in Alzheimer's patients. This formulation is designed for easier administration, especially in geriatric patients with swallowing difficulties. The company plans to begin its Phase II trial shortly after the initial batch is delivered. CEO Alejandro Antalich emphasizes the importance of addressing neurodegenerative diseases, highlighting the potential for improving patients' quality of life.
Biomind Labs has received FDA clearance for its New Chemical Entity Triptax™, marking a significant advancement in its clinical pipeline for treating treatment-resistant depression. The company also announced a loan facility of up to US$3,000,000 from its largest shareholder, Union Group Ventures Limited, intended for working capital. This facility will be repaid within 12 months and may involve issuing common shares. The company’s unaudited financial results for Q3 2022 are available on its SEDAR profile.
FAQ
What is the current stock price of Biomind Labs (BMNDF)?
What is the market cap of Biomind Labs (BMNDF)?
